Research to create a COVID-19 vaccine which can be administered through the nose has taken a significant step forward. The pre-clinical animal trials of the intranasal vaccine showed a reduction in both the impact of the disease itself and transmission of the virus.
Fewer than one in 20 children with symptomatic COVID-19 experienced symptoms lasting longer than 4 weeks, and almost all children have fully recovered by 8 weeks, a new study has found.
There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, immunologists write in a new article.
In a new study assessing the potential of a single-dose, intranasal COVID-19 vaccine, researchers found that the vaccine fully protects mice against lethal COVID-19 infection. The vaccine also blocks animal-to-animal transmission of the virus.
The body is filled with mucus that keeps track of the bacteria. Now, researchers present a method for producing artificial mucus. They hope that the artificial mucus, which consists of sugary molecules, may help to develop completely new, medical treatments.
Researchers have found that viral vaccines grown in eggs, such as the H1N1 flu vaccine, produce an antibody response against a sugar molecule found in eggs, which could have implications for the effectiveness of these vaccines.
Immunologists have discovered a previously unknown mechanism which acts like a spider web, trapping and killing pathogens such as influenza or SARS-CoV-2, the virus responsible for COVID-19.
Researchers discovered that a small subpopulation of antibodies binding to unique sites on each serotype are linked to protection. The research provides important information for vaccine developers to consider when creating a dengue vaccine, which has long eluded scientists.
Researchers have found a further reason for the severity of dual infection by influenza and Streptococcus pneumonia -- a new virulence mechanism for a surface protein on the pneumonia-causing bacteria S. pneumoniae. This insight comes 30 years after discovery of that surface protein, called pneumococcal surface protein A. This mechanism had been missed in the past because it facilitates bacterial adherence only to dying lung epithelial cells, not to living cells.
New research suggests there may someday be a role for ibuprofen in providing older adults with lasting immunity against RSV, a virus commonly associated with infants and young kids that also rivals the flu as a dangerous wintertime infection for the elderly.
Clusters of a virus known to cause stomach flu are resistant to detergent and ultraviolet disinfection, according to new research. The findings suggest the need to revisit current disinfection, sanitation and hygiene practices aimed at protecting people from noroviruses.
The virus that causes tick-borne encephalitis appears to trick the immune system, misdirecting it into producing inferior antibodies. But new research shows some people produce more potent antibodies, providing hope for treatment.
Influenza vaccines need to be evaluated every year to ensure they remain effective against new influenza viruses. Will the same apply to COVID-19 vaccines? Researchers compared the evolution of endemic 'common cold' coronaviruses with that of influenza viruses. The researchers predict that, while the pandemic is ongoing, vaccines will need to undergo regular updates. A few years into the post-pandemic period, however, vaccines are likely to remain effective for longer.
People who received a flu shot last flu season were significantly less likely to test positive for a COVID-19 infection when the pandemic hit, according to a new study. And those who did test positive for COVID-19 had fewer complications if they received their flu shot.
Infliximab, a powerful biologic that is used to treat inflammatory bowel disease (IBD), blunts the body's immune response to COVID-19 infection, new research indicates.
A significant proportion of hospitalized patients with influenza develop complications of acute respiratory distress syndrome. Investigators have found that treatment with an immune receptor blocker in combination with an antiviral agent markedly improves survival of mice infected with lethal influenza and reduces lung pathology in swine-influenza-infected piglets. Their research also provides insights into the optimal timing of treatment to prevent acute lung injury.